NASDAQ: CAPR · Biotechnology
Over the past week, Capricor Therapeutics (CAPR) drew about 331 mentions across Reddit, X and news, and the read is an Adanos Sell. The crowd averages 34% bullish but is deeply split: X runs 54% bullish while News sits at just 9%. Wall Street is more constructive, with 10 of 10 analysts rating CAPR a buy.
“CAPR is trending because of optimism around upcoming approval for DERAMIOCEL for DMD patients, offset by concern about the potential challenges of bringing this treatment to market.”Adanos /explain
Wall Street’s 100% buy share sits next to a crowd that ranges from News at 9% to X at 54%. No other tracker puts the two side by side.
Across 10 analysts the consensus is a Strong Buy: 10 buy calls against 0 sell, with an average 12-month price target of $4.38.
The Adanos signal blends each source’s bullish ratio, source breadth, buzz intensity and 3-day momentum. This week bullish sits just below the neutral line, momentum is mixed and the 3 sources disagree sharply, so the read is a Sell.
Analysts sit 66 points above the crowd average of 34%, the professionals are more constructive than retail. The split is inside the crowd: X reads 54% bullish while News sits at 9%, a 45-point spread that single-source trackers miss.
Over the 30-day window, Capricor Therapeutics (CAPR) buzz held elevated around 64.3 while the price drifted down 65.8% across the period. The chart tracks how social and news attention moved against end-of-day price. Average daily trading volume across the displayed trading days is 9.8M shares. Updated Aug 15, 2026. Over the last 7 trading days, CAPR gained 59.1%. Buzz activity in the recent week averaged 38.6 and was variable, swinging between 29.2 and 64.3. Recent volume is running above the 30-day average, suggesting heightened trading interest. Daily crowd sentiment leaned bullish on 10 of the 20 days with directional mentions, shown as the green, grey and red breakdown bars below the chart.
Signal metrics use the latest 7 days; contributor and breadth context uses the 30-day chart window.
No Polymarket data for this stock this week.
Query sentiment for CAPR and 2000+ stocks from your terminal. Filter by source, timeframe and signal strength.
View CLIEmbed live CAPR sentiment on your own site with drop-in web components.
View WidgetsThis week’s sentiment from Adanos, with fundamentals and analyst consensus. A quick-reference snapshot for Aug 15, 2026.
| Adanos signal | Sell |
|---|---|
| Analyst consensus | Strong Buy (10 / 0 / 0) |
| Crowd bullish (7d) | 34% |
| Avg price target | $4.38 |
| Most bullish source | X, 54% |
| Most bearish source | News, 9% |
| Sentiment spread | 45 pts |
| Mentions (7d) | 331 |
| Market cap | $386.4M |
| P/E · Forward P/E | n/a · 78.7 |
| EPS · Beta | -$2.45 · 0.5 |
| Revenue (TTM) | $11.1M · 0% margin |
| Industry | Biotechnology |
Based on aggregated sentiment from Reddit, X and News sources, Capricor Therapeutics (CAPR) currently carries an Adanos sell signal with 93/100 conviction. The current cross-source average reads 34% bullish across 3 active sources. Those sources contribute 331 tracked mentions over the last 7 days. This is a sentiment-based reading, not financial advice.
Reddit discussion around Capricor Therapeutics (CAPR) is fairly quiet with 64 mentions over the last 7 days; the 30-day context spans 13 tracked subreddits. The 7-day tone is 40% bullish; 3-day activity momentum is falling, suggesting cooling attention.
The crowd reads bearish on Capricor Therapeutics (CAPR), averaging 34% bullish across 3 tracked sources over the last 7 days. The two ends of the range are X at 54% bullish and News at 9%, a 45-point spread. On the professional side, 10 of 10 analysts rate CAPR a buy.
Of the 10 analysts covering Capricor Therapeutics (CAPR), 10 rate it a buy, 0 a hold and 0 a sell, for a strong buy consensus. The average price target is $4.38. That puts the street ahead of the crowd, which averages 34% bullish.
Capricor Therapeutics (CAPR)'s cross-source average is bearish at 34% bullish. Source readings are split: 1 source leans bullish and 2 sources lean bearish. Reddit reads 40% bullish, X reads 54% bullish and news coverage is the most negative at 9% bullish. The combined signal points to broad sell-side pressure with 93/100 conviction.
The cross-source average is bearish for Capricor Therapeutics (CAPR) at 34% bullish. Source readings are split: 1 source leans bullish and 2 sources lean bearish. The most bearish reading is news at 9% bullish. 3-day activity momentum is falling on Reddit, while news activity is rising. The sell signal carries 93/100 conviction.
X is the dominant discussion channel with 235 mentions (71% of total volume). Reddit contributes 64 mentions and News contributes 32 mentions. The cross-source average is bearish at 34% bullish, while news is the only source with rising 3-day activity. Source readings are split: 1 source leans bullish and 2 sources lean bearish.
The Adanos signal blends bullish ratio, buzz score, source breadth and 3-day activity momentum into a single buy/sell reading. CAPR's sell signal at 93/100 conviction reflects a bearish cross-source average at 34% bullish. Source readings are split: 1 source leans bullish and 2 sources lean bearish. It is a research shortcut, not financial advice.
The CAPR sentiment page is regenerated from the latest 7-day tracking window at each build. Data reflects the most recent Reddit posts, tweets and news articles available in the current publishing cycle.
Peers are ranked first by matching the Sell signal, then by the closest bullish ratio. Discussion activity breaks any remaining ties.
Every data point on this page comes from the Adanos sentiment APIs. Get a free API key and start querying Reddit, X, News and Polymarket sentiment programmatically.
Get Free API Key